Fengxi Su

5.9k total citations · 3 hit papers
55 papers, 4.6k citations indexed

About

Fengxi Su is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Fengxi Su has authored 55 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 22 papers in Cancer Research and 16 papers in Molecular Biology. Recurrent topics in Fengxi Su's work include Breast Cancer Treatment Studies (12 papers), Cancer Cells and Metastasis (9 papers) and HER2/EGFR in Cancer Research (9 papers). Fengxi Su is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), Cancer Cells and Metastasis (9 papers) and HER2/EGFR in Cancer Research (9 papers). Fengxi Su collaborates with scholars based in China, United States and Hong Kong. Fengxi Su's co-authors include Erwei Song, Herui Yao, Qiang Liu, Shicheng Su, Jianing Chen, Di Huang, Chang Gong, Jianing Chen, Fei Chen and Xiuying Cui and has published in prestigious journals such as Cell, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Fengxi Su

55 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness

2018 921 citations Shicheng Su, Jianing Chen et al. Cell profile →
A Positive Feedback Loop between Mesenchymal-like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis

2014 609 citations Shicheng Su, Qiang Liu et al. Cancer Cell profile →
CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3

2011 507 citations Jingqi Chen, Yandan Yao et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fengxi Su China	29	2.3k	2.2k	1.7k	1.5k	449	55	4.6k
Sonja Loges Germany	35	2.7k 1.2×	1.9k 0.9×	1.4k 0.8×	926 0.6×	630 1.4×	98	5.0k
Romain Boidot France	31	1.8k 0.8×	1.6k 0.7×	1.0k 0.6×	1.2k 0.8×	475 1.1×	112	4.0k
Hilary A. Kenny United States	27	2.6k 1.2×	1.8k 0.8×	2.1k 1.2×	1.1k 0.7×	393 0.9×	41	5.4k
Swarnali Acharyya United States	21	3.2k 1.4×	1.9k 0.9×	1.2k 0.7×	787 0.5×	595 1.3×	32	5.6k
Dingcheng Gao United States	26	2.8k 1.2×	2.5k 1.1×	1.8k 1.0×	936 0.6×	853 1.9×	36	5.1k
Anushka Dongre United States	11	2.0k 0.9×	1.8k 0.8×	1.2k 0.7×	764 0.5×	485 1.1×	15	3.8k
Sandra S. McAllister United States	24	2.3k 1.0×	2.8k 1.3×	1.2k 0.7×	1.1k 0.8×	1.1k 2.3×	46	5.1k
Lukas J.A.C. Hawinkels Netherlands	31	1.9k 0.8×	2.1k 0.9×	895 0.5×	1.6k 1.1×	590 1.3×	99	4.8k
P. Charles Lin United States	27	1.9k 0.8×	1.6k 0.7×	837 0.5×	1.6k 1.1×	300 0.7×	35	4.1k
Michael Hölzel Germany	33	2.2k 1.0×	1.7k 0.8×	588 0.3×	1.3k 0.9×	443 1.0×	96	4.3k

Countries citing papers authored by Fengxi Su

Since Specialization

Citations

This map shows the geographic impact of Fengxi Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengxi Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengxi Su more than expected).

Fields of papers citing papers by Fengxi Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengxi Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengxi Su. The network helps show where Fengxi Su may publish in the future.

Co-authorship network of co-authors of Fengxi Su

This figure shows the co-authorship network connecting the top 25 collaborators of Fengxi Su. A scholar is included among the top collaborators of Fengxi Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengxi Su. Fengxi Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Yingying, et al.. (2025). Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinoma. Clinical and Experimental Medicine. 25(1). 169–169. 1 indexed citations

Chen, Yanbo, et al.. (2025). Effects of Tai Chi Chuan on physical function and health in breast cancer patients. Supportive Care in Cancer. 33(2). 74–74. 1 indexed citations

Huang, Di, Xueman Chen, Xin Zeng, et al.. (2021). Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer. Nature Immunology. 22(7). 865–879. 71 indexed citations

Li, Chenchen, Yujie Tan, Jianli Zhao, et al.. (2019). Multiple metastases of bones and sigmoid colon after mastectomy for ductal carcinoma in situ of the breast: a case report. BMC Cancer. 19(1). 844–844. 2 indexed citations

Tan, Luyuan, Liling Zhu, Lei Xin, et al.. (2019). <p>Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study</p>. Cancer Management and Research. Volume 11. 8379–8389. 13 indexed citations

Li, Huiping, Jiang Liu, Jianing Chen, et al.. (2018). A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nature Communications. 9(1). 1614–1614. 84 indexed citations

Su, Shicheng, Jinghua Zhao, Yue Xing, et al.. (2018). Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell. 175(2). 442–457.e23. 230 indexed citations

Nie, Yan, Jianing Chen, Di Huang, et al.. (2017). Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation. Cancer Research. 77(13). 3605–3618. 43 indexed citations

Su, Shicheng, Jian‐You Liao, Jiang Liu, et al.. (2017). Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Research. 27(4). 461–482. 173 indexed citations

10.

Jia, Weijuan, Jiannan Wu, Haixia Jia, et al.. (2015). The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS ONE. 10(11). e0143061–e0143061. 88 indexed citations

11.

Liu, Jieqiong, Wen Jiang, Kai Mao, et al.. (2015). Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Research and Treatment. 150(2). 439–445. 31 indexed citations

12.

Tang, Lu-Ying, Yi Su, Jianrong He, et al.. (2012). Urinary Titanium and Vanadium and Breast Cancer: A Case-Control Study. Nutrition and Cancer. 64(3). 368–376. 14 indexed citations

13.

He, Jianrong, Lu-Ying Tang, Dandan Yu, et al.. (2011). Epstein-Barr virus and breast cancer: Serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Letters. 309(2). 128–136. 43 indexed citations

14.

Zhu, Yinghua, Fengyan Yu, Yu Jiao, et al.. (2011). Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5. Clinical Cancer Research. 17(22). 7105–7115. 211 indexed citations

15.

Chen, Jingqi, Yandan Yao, Fengyan Yu, et al.. (2011). CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3. Cancer Cell. 19(6). 814–816. 18 indexed citations

16.

Gong, Chang, Herui Yao, Qiang Liu, et al.. (2010). Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer. PLoS ONE. 5(12). e15630–e15630. 61 indexed citations

17.

Su, Fengxi, et al.. (2006). Highs without lows. The New Scientist. 27(2550). 25–3. 3 indexed citations

18.

Su, Fengxi, Nengyong Ouyang, Pengcheng Zhu, et al.. (2005). Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochemical and Biophysical Research Communications. 329(3). 888–897. 61 indexed citations

19.

Song, Erwei, et al.. (2001). Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. The American Journal of Surgery. 181(6). 529–533. 31 indexed citations

20.

Chen, Jisheng, et al.. (2001). Adenovirus-mediated Bcl-2 gene transfer inhibits apoptosis and promotes survival of allogeneic transplanted hepatocytes. Surgery. 130(3). 502–511. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact